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The GABAergic system is central to the development and functional maturation of
the nervous system. Emerging evidence support the role of GABAergic dysfunction in
neuro-developmental disorders. This review presents the molecules and mechanisms that
underlie GABA system dysfunction in several neuro-developmental disorders presenting
in childhood. The impact on synaptic plasticity, neuronal circuit function and behavior,
followed by targeted treatment strategies are discussed.
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INTRODUCTION
Neuronal circuits undergo structural refinement in response to
changes in experience. Although this ability is present through-
out life, there are sensitive periods of elevated plasticity when
the brain is capable of intense restructuring of synaptic connec-
tions (Wiesel and Hubel, 1963; Knudsen, 2004; Hensch, 2005).
These periods of elevated plasticity occur early in postnatal life
and are triggered by a unique excitatory—inhibitory (E/I) balance
that sets in motion a cascade of molecular events. These molec-
ular events lead to structural changes and closure of the critical
period. Critical periods sub-serving the acquisition of different
skills occur on different time scales and in multiple brain regions.
While they offer tremendous opportunities, they are periods of
great vulnerability for the developing brain and critical period
dysfunction is linked to several neuro-developmental disorders.
The complexity of neural circuits results in part from the
rhythmic inhibitory activity of GABAergic interneurons that syn-
chronize the spiking of local pyramidal cell ensembles, thus
maintaining homeostatic levels of activity in the brain (Somogyi
et al., 1998;Markram et al., 2004; Somogyi and Klausberger, 2005;
Kullmann, 2011). These processes act to enhance the efficiency of
information processing by increasing the likelihood of coincident
spiking and action potential firing in downstream neurons.
There are several different classes of GABAergic interneurons.
Among them are fast-spiking, parvalbumin (PV) positive bas-
ket cells which account for 50% of GABAergic interneurons in
rodent cortex and are required for the generation of fast rhyth-
mic, synchronous activity (Markram et al., 2004). A single PV+
interneuron innervates hundreds of pyramidal neurons in the
mature cortex (Somogyi et al., 1998). Studies have shown that
PV interneurons regulate the developmental increase in inhi-
bition that eventually leads to decrease plasticity, and triggers
the closure of the critical period in the visual cortex (Heimel
et al., 2011). Perturbations in the GABAergic system is linked
to alterations in E/I balance, disruption in the critical period,
improper development, and function of neural circuits. This leads
to aberrant information processing, and cognitive deficits in a
variety of neuro-developmental disorders. This review focuses
on the GABAergic system dysfunction in Down syndrome, Rett
syndrome, Fragile X syndrome, and Autism and therapeutic
strategies.
DOWN SYNDROME
Down syndrome (DS) is the most common non-inherited cause
of intellectual disability and results from triplication of chro-
mosome 21. The cognitive phenotypes of DS are reproduced
in Ts65Dn mice, a model of Down syndrome and are posited
to result from imbalance in excitation and inhibition. Several
genes involved in the GABAergic systems are present on chro-
mosome 21 and are triplicated in DS and the Ts65Dn mice.
These include Olig1/2 and Grik2. Olig1 and Olig2 are over-
expressed in the medial ganglionic eminence (MGE) of Ts65Dn
brain at E14.5 (Chakrabarti et al., 2010). There are more Olig2+
cells in the Ts65Dn MGE compared to euploid littermates at
E13.5 and E14.5 when cohorts of cortical interneurons arise.
Olig1/Olig2 over-expression is thought to be the genetic basis of
the interneuron over-production in the Ts65Dn brain. Reducing
the gene dosage of Olig2 in Ts65Dn mice rescued the interneu-
ron over-production phenotype, and normalized the frequency of
spontaneous inhibitory postsynaptic currents (sIPSC). G-protein
coupled inward-rectifying potassium (GIRK2) containing chan-
nels are over-expressed in Ts65Dn mice (Harashima et al., 2006).
These channels are activated by agonists at Gi/o coupled receptors
such as the GABAB receptor (Sodickson and Bean, 1996). Their
pattern of expression mirrors the expression of GABAB receptors
and Grik2, and GABAB receptors are more intensely expressed
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in the stratum lacunosum moleculare (SLM) when compared to
the other layers of the CA1 (Sloviter et al., 1999; Lopez-Bendito
et al., 2004; Harashima et al., 2006). The SLM is expected to
have larger synaptically evoked inhibitory currents (Pham et al.,
1998) and likely serve as primary modulators of the direct per-
forant pathway inputs into CA1, thus playing important roles in
learning and memory (Sybirska et al., 2000; Brun et al., 2002).
Elevated GABAB receptor dependent GIRK channel current den-
sity was observed in CA1 of Ts65Dn mice and occurred without
differences in GABA release probability was (Best et al., 2007,
2012). In addition, the ratio of monosynaptic GABAB/GIRK to
GABAA currents was significantly elevated in Ts65Dn mice upon
SLM stimulation in the absence of changes in GABAA subunit
expression or function. The experiments described by Best et al.
(2012) attribute the altered GABAergic transmission in area CA1
of Ts65Dn mice to increase function of the GABAB/GRIK com-
plexes. In contrast, data from Kleschevnikov et al., demonstrates
enhanced GABAA and GABAB receptor-mediated evoked IPSCs
in the DG granule cells with decrease in paired-pulse ratio sug-
gesting an increase in presynaptic release (Kleschevnikov et al.,
2004). Together these data suggest that there are region spe-
cific mechanisms underlying GABAergic signaling deficits within
theTs65Dn hippocampus.
Several groups show a decrease in the number of excitatory
synapses and a relative increase in the inhibitory synaptic markers
in the cortex and hippocampus of adult Ts65Dnmice (Belichenko
et al., 2004, 2009; Perez-Cremades et al., 2010). Consistent with
these findings the number of inhibitory interneurons is increased
in Ts65Dn mice (Chakrabarti et al., 2010). Experiments designed
to examine the functional relevance of the increase in synaptic
markers show that the rate of sIPSC is higher in the pyramidal
cell layer of CA1 in Ts65Dn mice. Moreover, there were no differ-
ences in the frequency of mIPSC or in the paired pulse ratio. This
finding is consistent with an increase in the number of functional
interneurons and is inconsistent with an increase in number of
inhibitory synapses or enhanced probability of GABA release in
CA1 (Chakrabarti et al., 2010; Best et al., 2012; Mitra et al., 2012).
Developmental assessment of the IPSC shows a transient increase
in evoked inhibition and mIPSC in Ts65Dn mice during the sec-
ond postnatal week but not in the first or third postnatal week,
when stimulation is performed in the stratum radiatum or pyra-
midale (Mitra et al., 2012). This transient disruption in inhibitory
synaptic transmission occurs during the critical period of neu-
ronal network development and could contribute to later network
dysfunction seen in adult mice.
Enhanced GABA-mediated inhibition in several hippocam-
pal sub-regions is associated with a marked reduction in
long-term potentiation (LTP) in the CA1 and DG. Several
groups have rescued LTP upon acute or chronic treatment of
Ts65Dn hippocampus with GABA antagonist (Siarey et al., 1997;
Kleschevnikov et al., 2004; Costa and Grybko, 2005; Fernandez
and Garner, 2008). Consistent with these findings and a role for
GABA in learning and memory, modulators of GABA receptor
function have been used to rescue cognitive phenotypes in
the Ts65Dn mice. The non-competitive GABAA antagonist
pentylenetetrazole (PTZ), and the GABA antagonist picrotoxin
and bilobalide normalized cognitive function measured by object
recognition (Fernandez et al., 2007), while chronic administra-
tion of PTZ rescued the performance of Ts65Dn mice in Morris
water maze (Rueda et al., 2008). Moreover, RO4938581 (3-
bromo-10-(difluoromethyl)-9H-benzo_f_imidazo[1,5-a][1,2,4]
triazolo[1,5-d][1,4]diazepine), a selective GABA A _5 NAM,
rescued hippocampal LTP and hippocampal dependent cognitive
deficits in Ts65Dn mice (Martinez-Cue et al., 2013), and the
GABA-A-benzodiazepine receptor inverse agonist selective for
the a5-subtype (a5IA) restored learning and memory in novel
object and Morris water maze in Ts mice (Braudeau et al., 2011).
GABAB receptor antagonism relevant to DS since the GABAB
receptor antagonist CGP55845 improved contextual memory
in fear-conditioning task in Ts65Dn mice (Kleschevnikov et al.,
2012). Clinical trials are underway to study the effect of GABA
antagonism on cognitive phenotypes in DS.
RETT SYNDROME
Rett syndrome (RS) is the leading genetic cause of intellectual
disability in girls. It is caused by mutations in the transcrip-
tional repressor methyl-CpG-binding protein 2 (MeCP2). The
MECP2 protein regulates gene expression by DNA methylation
and MeCP2-mutant mice recapitulate many of the phenotypes
RS. These mice, like girls with RS appear phenotypically nor-
mal early during development and then undergo severe regression
with resulting impairment in respiratory function, loss of hand
use, impairment in language, and motor function. Several studies
suggest that an imbalance in excitatory and inhibitory neuro-
transmission contributes to the behavioral abnormalities in RS
(Dani et al., 2005; Asaka et al., 2006; Moretti et al., 2006).
In early postnatal life before respiratory abnormalities become
apparent, a shift in the E/I balance toward excitation is seen in the
ventrolateral medulla of MeCP2 null mice. This shift results from
a disruption in both presynaptic and post-synaptic mechanisms
of the excitatory and inhibitory pathways (Medrihan et al., 2008).
This is in contrast to the increase in inhibitory and reduction
in excitatory inputs to L5 pyramidal neurons in the somatosen-
sory cortex during the second postnatal week, also before onset of
overt symptoms. The direction of the shift is brain region spe-
cific and this is readily apparent in thalamic networks. In the
absence of MeCP2, a reduction in frequency of mIPSC in the ven-
trobasal complex (VB) of the thalamus is observed during the
first through third postnatal week but an increase in frequency
of mIPSC was observed from the second through third postnatal
week in the reticular thalamic nucleus (RTN) (Zhang et al., 2010).
A further example of brain region specific change is the shift of
E/I balance in favor of inhibition reported in the visual cortex of
MeCP2 null mice. Parvalbumin (PV) levels and the number of
PV positive interneurons were increased, while the mRNA of the
calcium-binding proteins, calretinin, and calbindin were reduced.
In addition, perisomatic boutons were increased in MeCP2 KO
mice and this increase was evident at the time of eye opening.
PV+ interneurons synapse onto the soma and proximal dendrites
of principal cells to control their excitability and adjust the gain of
their integrated synaptic response (Markram et al., 2004; Atallah
et al., 2012). Maturation of these PV circuits in visual cortex is
modulated by sensory experience. Dark-rearing from birth (DR)
specifically reduces perisomatic inhibition (Katagiri et al., 2007;
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Sugiyama et al., 2008) and delays onset of the heightened period
of visual cortical plasticity. Dark rearing at P30 in the absence of
MeCP2 was sufficient to rescue PV-cell hyper-connectivity and
improve visual acuity to near WT levels in the adult MeCP2 null
mice. Restoration of visual acuity was associated with normal-
ization of PV levels, a reduction in the number of perisomatic
boutons and reduction in spontaneous firing rates of MeCP2 KO
mice to that of control WT cells (Durand et al., 2012).
The experiments described above clearly demonstrate a criti-
cal role for MeCP2 in regulation of GABAergic transmission. The
cellular and molecular mechanisms underlying MeCP2-mediated
regulation of GABAergic transmission are diverse and highly cir-
cuit dependent. Several studies show that BDNF regulates the
formation and maturation of GABAergic synapses (Huang et al.,
1999; Marty et al., 2000; Hong et al., 2008), and the reduc-
tion of BDNF in single cortical neurons caused a reduction
in the frequency of mIPSC without change in peak amplitude
(Kohara et al., 2007). Indeed, BDNF is regulated by MeCP2 in
an activity dependent manner (Zhou et al., 2006) and BDNF lev-
els are reduced in MeCP2 null mice (Chang et al., 2006; Wang
et al., 2006). Intriguingly, MeCP2 null mice that are raised in
an enriched environment (EE) starting at P10 show increase in
BDNF levels and normalization of LTP and spatial memory when
measured in adult mice (Lonetti et al., 2010). The normalization
of synaptic plasticity and behavior occurs in the context of an
increase in the density of excitatory synapses in the somatosen-
sory cortex with no changes in the density of inhibitory synapses
(Lonetti et al., 2010). EE have previously been shown to cause
a functional reduction in cortical inhibition (Sale et al., 2007),
whether a similar mechanism contributes to the amelioration of
behavioral and plasticity deficits in MeCP2 null mice reared in an
EE is not known. These data suggest that the interplay between
MeCP2 and BDNF on the balance between E/I is complex and
can be further modulated by environmental context.
FRAGILE X SYNDROME
Fragile X syndrome (FXS) is the most common single gene
cause of intellectual disability and autism (Kaufmann et al., 2004;
Hagerman et al., 2005). It results from loss of function muta-
tions in the fmr1 gene that encodes FMRP (Verkerk et al., 1991;
O’Donnell and Warren, 2002). The FX phenotypes of cogni-
tive impairment, hypersensitivity to sensory stimuli, epilepsy, and
characteristics of autism are recapitulated in the Fmr1 knockout
(KO)mouse a model of FXS (Musumeci et al., 2000; Nielsen et al.,
2002; Spencer et al., 2005; Brennan et al., 2006). An imbalance in
excitation and inhibition is posited to be central to the etiologic
mechanisms of Fragile X.
Several studies have suggested a role for disruption of the
GABAergic system in FXS and report abnormal GABA-mediated
transmission in FX KOmice. Impairment in the excitatory inputs
onto fast spiking (FS) interneurons and impairment in group 1
mGluR activation of low-threshold-spiking (LTS) interneurons
have been reported in FX mice (Gibson et al., 2008; Paluszkiewicz
et al., 2011). The inhibitory output of the FS and LTS interneu-
rons typically increase in response to network activation (Kapfer
et al., 2007; Silberberg and Markram, 2007), thus making them
well positioned to dynamically control cortical network function.
In FX mice this disruption in activation of FS and LTS is
implicated in cortical hyperexcitability manifesting as altered UP
States and inhibitory network dysfunction in layerII/III of the
somatosensory cortex.
GABAA receptors are heteropentamers, and their subunit
composition is an important determinant of inhibitory transmis-
sion, subcellular localization, and sensitivity to clinically relevant
compounds (Hevers and Luddens, 1998; Sieghart and Sperk,
2002; Rudolph and Mohler, 2006). Expression studies reveal that
mRNAs that encode the GABAA α1, α3, α4 receptor subunits
are decreased in adult Fmr1 KO mice (El Idrissi et al., 2005;
Gantois et al., 2006; D’Hulst et al., 2009). Protein levels of GABAA
receptor α1, β2, and δ subunits are transiently down regulated at
postnatal day 12 and all but GABAA β2 subunits were restored
to normal levels in adult mice. GABAA receptor α1 subunit is
the most abundant of all GABAA receptor subunits (Mohler,
2007; Olsen and Sieghart, 2009), they account for about half of
all GABAA subunits and are widely expressed in the CNS. The
reduction of GABAA receptors at P12 is posited to cause a reduc-
tion in excitation in the second week of postnatal development
at a time when GABAergic synaptic activity is thought to play a
critical role in the maturation of functional inhibitory synapses
(Ben-Ari, 2002; Cancedda et al., 2007). Thus, the down regula-
tion of the GABAA receptor subunits at P12may lead to structural
alterations of synapses that result in the characteristic presence of
immature dendritic spines in FXS.
Presynaptic increases and decreases in the expression of the
GABA-synthesizing enzyme GAD have been reported in Fmr1
KOs (El Idrissi et al., 2005; D’Hulst and Kooy, 2009; Adusei et al.,
2010; Olmos-Serrano et al., 2010). The direction of the change
is due in part to the brain region examined. Olmos-Serrano and
colleagues report that GAD65/67 protein expression is reduced
in the basolateral amygdala, and this finding is complemented
by decreased vesicular GABA levels. In contrast GAD65/67 levels
were increased in the cortex, hippocampus, brainstem, and dien-
cephalon (El Idrissi et al., 2005; Adusei et al., 2010). Transient
down regulation of the catabolic enzymes GABA-T and suc-
cinic semialdehyde dehydrogenase are reported in the forebrain of
FMRP null mice at P12 (Adusei et al., 2010) and may compensate
for the decrease levels of GABAA receptor subunits to effectively
increase GABAergic transmission by increasing GABA levels.
FMRP KO mice exhibit variable and region specific disrup-
tions in functional inhibitory transmission in behaviorally rel-
evant brain regions. Inhibitory dysfunction in the basolateral
amygdala is characterized by reductions in the frequency and
amplitude of spontaneous IPSCs and changes in IPSC kinetics.
These findings are consistent with report of decreased GABAA
receptor subunit, GAD expression, vesicular GABA, and impaired
GABA release (Olmos-Serrano et al., 2010). In contrast, striatal
neurons demonstrate an increase in basal inhibitory transmission
driven by increased GABA release as show by the increase in the
frequency of sIPSCs, mIPSCs, and reduction in PPR of evoked
IPSCs (Centonze et al., 2008).
GABAergic dysfunction in FMRP KO mice is mediated by
presynaptic and post synaptic mechanisms that are brain region
and receptor subtype dependent. With this in mind preclini-
cal and clinical trials have examined the therapeutic relevance
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of GABAA and GABAB receptors in FXS. THIP (gaboxadol),
a GABAA receptor agonist, that acts upon tonic GABA recep-
tors significantly attenuated hyperactivity and prepulse inhibi-
tion in Fmr1 KO mice, but did not reverse the deficits in cued
fear or startle response (Olmos-Serrano et al., 2011). Activation
of the GABAB receptor with STX209 (arbaclofen, R-baclofen)
corrected synaptic abnormalities, reduces protein synthesis, cor-
rect enhanced AMPAR trafficking, and suppressed audiogenic
seizures in FMRP KO mice (Pacey et al., 2009; Henderson et al.,
2012). Moreover, STX209 when used in a clinical trial showed
improved social function in patients with FXS (Berry-Kravis et al.,
2012). Additional clinical trials are underway to test the ability
of STX209 to reduce aggression and irritability in FXS. The vari-
able mechanism by which GABA dysfunction contributes to the
FX phenotype poses interesting challenges to treatment that may
require the use of combination therapies.
AUTISM
Autism Spectrum Disorder is postulated to result in part from
deficient GABA neurotransmission. Reduced GABAA receptors
and benzodiazapine binding sites are reported in the hippocam-
pus and cingulate gyrus from neuropathological samples from
individuals with autism (Blatt et al., 2001; Oblak et al., 2009,
2010). Consistent with the findings in autopsy samples, direct
measurement of GABAA receptors and GABA concentration in
the living brain of children with ASD using SPECT (Single Photon
Emission Computed Tomography) and [1H]MRS showed a
reduction in GABAA receptor levels and GABA concentration
in the frontal cortex (Harada et al., 2011; Mori et al., 2012).
Examination of GABAA receptor levels in the brains of adults
with ASD, using Positron Emission Tomography (PET) and the
benzodiazepine receptor PET ligand [11C]Ro15-4513, showed
a reduction in 11C] Ro15-4513 binding in the amygdala and
nucleus accumbens (Mendez et al., 2013).
Converging on neuropathological and imaging data, genetic
studies reveal a role for GABAergic dysfunction in ASD.
Microduplications/deletions of the 15q11- q13 chromosomal
locus, known to contain GABAA a5, b3, and g3 subunits, have
been observed in some individuals with ASD (Cook et al., 1998;
Menold et al., 2001; Buxbaum et al., 2002; Shao et al., 2003;
McCauley et al., 2004; Sebat et al., 2007). Duplication of this
locus is expected to result in over expression of the GABAA
receptor subunits, however, in vitro studies using human neu-
ronal cell line carrying the 15q duplication showed a reduction
in GABRB3 expression (Meguro-Horike et al., 2011). The asso-
ciation of genetic polymorphisms in the DLX1/2 genes provides
additional support of the GABAergic model for autism (Liu et al.,
2009). In addition, transciptomic analysis of autopsy samples
from autistic brains found reduced cortical mRNA expression of
genes that are highly expressed in PV+ interneurons (Voineagu
et al., 2011). Together these studies provide strong convergent
evidence for an inhibitory deficit in autism.
CONCLUSION
The volume of evidence in support of GABAergic dysfunction in
neuro-developmental disorders is overwhelming. Although the
mechanism and manifestation of GABA dysfunction is disease
and brain region/circuit specific, current evidence supports
impaired GABA transmission during the critical period followed
by GABAergic dysfunction in the adult animal. Current efforts
to treat the disorders discussed have had variable results. One
approach worthy of consideration involves reintroducing a period
of elevated plasticity in the adult animal. Such approach hasmajor
hurdles. It requires a detailed understanding of GABAergic dys-
function, methods for reopening the critical period sub-serving
the acquisition of different skills and the impact of such manipu-
lations on other brain regions. Much can be learned from efforts
to treat amblyopia by re-opening the critical period. Several
groups have reintroduced juvenile plasticity in the adult brain
of rodents by directly removing the perineuronal nets (PNN), a
structural barrier to plasticity thus enabling recovery from ambly-
opia (Pizzorusso et al., 2002; Sale et al., 2007; Soleman et al.,
2013). Manipulations that adjust the E/I balance either by direct
transplantation of embryonic GABA precursor cells into the post-
natal brain (Southwell et al., 2010) or the endogenous release of
serotonin through chronic treatment with fluoxetine have opened
a second critical period that restores visual function in amblyopic
adult rats (Maya Vetencourt et al., 2008). Chronic administration
of fluoxetine mediates its effect through the reduction of intra-
cortical inhibition and increase in BDNF levels (Maya Vetencourt
et al., 2008) possibly allowing activation of plasticity genes and
modulation of neuronal circuits involved in ocular dominance.
Environmental enrichment through enhanced sensory-motor
stimulation rescued spatial learning and visual acuity in adult
Ts65Dn mice (Begenisic et al., 2011). These changes occur in
association with a reduction in GABA release and normalization
of hippocampal LTP. These findings are consistent with previous
reports that show reduced cortical inhibition and increased neu-
ronal plasticity in the brains of adult rats exposed to an EE (Sale
et al., 2007). Moreover, the restoration of near normal visual acu-
ity in MeCP2 null mice upon dark rearing at P30 is encouraging,
and suggests that reopening the critical period maybe a thera-
peutic option for neuro-developmental disorders. There has been
some success at restoring vision in human adults with ambly-
opia (Bavelier et al., 2010) but the need to better understand the
extent to which sensitive periods can be safely and noninvasively
recapitulated remains an exciting challenge.
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